OraSure Technologies (NASDAQ:OSUR) Releases Quarterly Earnings Results, Misses Estimates By $0.04 EPS

OraSure Technologies (NASDAQ:OSUR) released its quarterly earnings results on Wednesday. The medical instruments supplier reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04), Zacks reports. OraSure Technologies had a negative return on equity of 13.61% and a negative net margin of 47.92%.

Here are the key takeaways from OraSure Technologies’ conference call:

• Submitted two FDA applications in December for a rapid molecular OTC self-test for chlamydia/gonorrhea (Sherlock) and the Colli‑Pee at‑home urine collection device, targeting mid‑year launches and a revenue ramp in H2 2026; management cites a CT/NG TAM of >$1.5 billion.
• International diagnostics trends are stabilizing and OTI is pursuing nearshoring (in‑country assembly in Africa) and integrating BioMedomics to expand distribution of the Sickle SCAN test, with revenue contributions expected beginning in Q1 and through 2026.
• Q4 revenue was $26.8M (core $26.7M) above midpoint guidance and GAAP gross margin improved to 41%; the company ended 2025 with $199M cash, zero debt and $15M of buybacks, but reported a GAAP operating loss of $20.1M and negative operating cash flow, guiding Q1 revenue of $26–29M and expecting operating cash flow breakeven by 2027.
• Operational actions—manufacturing consolidation to Bethlehem, internalizing contract volumes, and an expected decline in R&D as clinical trials wind down—should drive sequential gross margin improvement as capacity utilization increases with revenue growth.

OraSure Technologies Trading Down 0.7%

NASDAQ OSUR traded down $0.02 on Wednesday, reaching $2.80. 539,717 shares of the stock were exchanged, compared to its average volume of 505,879. OraSure Technologies has a one year low of $2.08 and a one year high of $4.22. The firm has a market capitalization of $200.84 million, a PE ratio of -3.50 and a beta of 0.87. The company’s 50-day simple moving average is $2.65 and its two-hundred day simple moving average is $2.79.

Institutional Trading of OraSure Technologies

Several institutional investors and hedge funds have recently modified their holdings of the company. Invesco Ltd. boosted its holdings in OraSure Technologies by 11.1% in the 4th quarter. Invesco Ltd. now owns 161,182 shares of the medical instruments supplier’s stock worth $390,000 after buying an additional 16,041 shares during the period. XTX Topco Ltd lifted its position in shares of OraSure Technologies by 57.8% in the fourth quarter. XTX Topco Ltd now owns 121,144 shares of the medical instruments supplier’s stock valued at $293,000 after acquiring an additional 44,379 shares in the last quarter. Quadrature Capital Ltd bought a new position in shares of OraSure Technologies in the fourth quarter worth about $28,000. Numerai GP LLC bought a new position in shares of OraSure Technologies in the fourth quarter worth about $100,000. Finally, Odyssean LLC purchased a new stake in shares of OraSure Technologies during the fourth quarter worth about $162,000. 93.50% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. Weiss Ratings reissued a “sell (d)” rating on shares of OraSure Technologies in a report on Thursday, January 22nd. Stephens reduced their price target on shares of OraSure Technologies from $3.50 to $3.00 and set an “equal weight” rating for the company in a research report on Wednesday, November 12th. Two investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Reduce” and a consensus target price of $3.00.

OraSure Technologies Company Profile

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.